Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis: Ontario Ministry of Health Perspective

Author： Marshall J.K.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.19, Iss.10, 2001-01, pp. : 1039-1049

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valuing Health States for Use in Cost-Effectiveness Analysis

By Brazier John  

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 769-779

Adis International

Access to resources Recommend Favorite

Rofecoxib cost-effectiveness study results debated

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 455, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

By Jansen Jeroen P.  

PharmacoEconomics, Vol. 28, Iss. 4, 2010-04 ,pp. : 323-344

Adis International

Access to resources Recommend Favorite

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine   Shabaruddin Fatiha H  

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) Programme: A Canadian Teaching Hospital and Ministry of Health Perspective

By Wai A.O.   Frighetto L.   Marra C.A.   Chan E.   Jewesson P.J.  

PharmacoEconomics, Vol. 18, Iss. 5, 2000-11 ,pp. : 451-457

Adis International

Access to resources Recommend Favorite